Agios Pharmaceuticals, Inc. (AGIO)
$
40.92
+0.31 (0.76%)
Key metrics
Financial statements
Free cash flow per share
-7.0604
Market cap
2.4 Billion
Price to sales ratio
58.1655
Debt to equity
0.0356
Current ratio
14.4790
Income quality
-0.6245
Average inventory
30.2 Million
ROE
0.4331
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering and developing medicines within the realm of cellular metabolism and related biological areas. The company delivers pivotal treatments such as PYRUKYND (mitapivat), an activator for both wild-type and various mutant pyruvate kinase (PK) enzymes targeted at addressing hemolytic anemias. Additionally, Agios is advancing AG-946, currently in Phase I clinical studies for treating hemolytic anemias and other medical indications. Financially, the company earned an interest income of $48,083,000.00 showcasing its strategic financial investments. The income before tax ratio is 19.67 reflecting the pre-tax margin and indicating a robust operational capacity. However, the net total of other income and expenses is $1,143,706,000.00 which illustrates the influence of non-core financial activities on the overall financial picture. Moreover, the company reported depreciation and amortization expenses of $5,653,000.00 which reflect the wear and tear of its physical and intangible assets. The gross profit ratio is 0.89 indicating the efficiency of the company's production and sales operations in maintaining profitability while advancing its innovative drug portfolio. As a notable entity in the biopharmaceutical landscape, Agios Pharmaceuticals operates within a mid-range market capitalization of $2,377,514,117.00 positioning itself as a steady performer in the industry. The stock is affordable at $37.70 making it suitable for budget-conscious investors looking to engage in this sector. Additionally, the stock has an average trading volume of 784,475.00 indicating moderate liquidity, which is essential for investors considering market entry. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape and driving forward innovation and growth. Positioned within the Healthcare sector, Agios Pharmaceuticals reflects a commitment to advancing healthcare solutions while fostering economic stability through its strategic investment and operational initiatives.
Is Agios Pharmaceuticals, Inc. (AGIO) a good investment?
Investing in Agios Pharmaceuticals, Inc. (AGIO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
What is Agios Pharmaceuticals, Inc. (AGIO)'s stock forecast?
Analysts predict Agios Pharmaceuticals, Inc. stock to fluctuate between $23.42 (low) and $62.58 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Agios Pharmaceuticals, Inc.'s market capitalization?
As of 2025-10-13, Agios Pharmaceuticals, Inc.'s market cap is $2,377,514,117, based on 58,101,518 outstanding shares.
How does Agios Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Agios Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Agios Pharmaceuticals, Inc. (AGIO) stock?
To buy Agios Pharmaceuticals, Inc. (AGIO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AGIO. Place an order (Market, Limit, etc.).
What is the best time to invest in Agios Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Agios Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $36,498,000 | EPS: $11.86 | Growth: -287.36%.
Where can I find Agios Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.agios.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Agios Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Agios Pharmaceuticals, Inc. stock?
All-time high: $62.58 (2024-11-11) | All-time low: $16.75 (2022-06-16).
What are the key trends affecting Agios Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO).
globenewswire.com
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
prnewswire.com
LOS ANGELES , Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or "the Company") (NASDAQ: AGIO) for violations of the securities laws.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)---- $AGIO--AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
prnewswire.com
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO).
globenewswire.com
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
prnewswire.com
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO).
seekingalpha.com
Agios faces a pivotal FDA decision on 7 December for mitapivat's thalassemia expansion, with a good chance of approval based on strong Phase 3 data. The stock has lagged typical pre-PDUFA momentum, offering an attractive entry point for risk-tolerant investors ahead of a potential catalyst. Safety concerns exist but are likely manageable with enhanced monitoring; Agios' robust cash position provides a buffer against regulatory setbacks.
See all news
